We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees
Oxford Immunotec announces preliminary fourth quarter revenues
Oxford University Innovation announced that OxSonics has raised £2.7 million to develop therapeutic technology which uses ultrasound devices in combination with ultrasound-sensitive nanoparticles.
Immunocore has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
Colwiz has announced the launch of the first HTML5 interactive PDF reader.
Reviving a gene which is “turned down” after birth is potentially the key to treating Duchenne Muscular Dystrophy, an untreatable muscle-wasting condition which affects one in every 3,500 boys.
Oxford Immunotec – a 2002 Isis spin-out – has raised US$64 million in an IPO on America’s Nasdaq stock exchange. The Abingdon-based company sells diagnostic tests for latent tuberculosis infection, T-SPOT®.TB.
Immunocore Limited, the Oxford based biotechnology company developing novel biological drugs to treat cancer and viral disease has announced the achievement of its first milestone in its research and licensing agreement with GlaxoSmithKline.
Oxford University Innovation spin-outs, Oxford Gene Technology and OrganOx have won an award each at the OBN Annual Awards Dinner held on 1st October. The OBN is a membership organisation supporting and bringing together the UK’s emerging life science R&D companies, their corporate partners and investors.
Oxford Risk Ltd, a spin-out of the University of Oxford, has developed an online Risk Profiling service that gives both individual investors and financial advisers access to professional risk assessments. An accurate risk assessment is the first step in matching the investor’s preferences to the right investment, and can enhance transparency in the wealth management process. The web-based system, Oxford Risk Rating Online, follows Financial Service Authority guidelines that require advisers take reasonable steps to ensure that investment recommendations are suitable for their customers.
As the technology commercialisation company of Oxford University, Oxford University Innovation, celebrates its 25th anniversary, it also looks back on 101 companies that originate from Isis. Oxford Biotrans, the 101st company, will commercialise new routes to high-value chemicals using patented enzyme technology.
